Skip to content

Is Platelet Rich Plasma Superior to Local Steroids Injection in Lateral Epicondylitis at 24 months? A multicenter randomized controlled trial

Is Platelet Rich Plasma Superior to Local Steroids Injection in Lateral Epicondylitis at 24 months? A multicenter randomized controlled trial

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000038828
Enrollment
Unknown
Registered
2020-10-05
Start date
2015-02-03
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lateral Epicondylitis

Interventions

2:Steroid injection

Sponsors

Ghurki Trust and Teaching hospital, Lahore, Pakistan
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: We included patients that were 18 years and above and had lateral elbow pain for more than 12 weeks and were dissatisfied with the results of previous conservative treatment options. The diagnosis of tennis elbow was established clinically if the patients had lateral elbow pain with the maximum of point of tenderness at the insertion of extensor carpi brevis (ECRB), and the pain intensified on gripping, resisted wrist extension and compression of lateral epicondyle.

Exclusion criteria

Exclusion criteria: Patients were excluded if they had previous surgery on the affected elbow or a traumatic injury on the affected limb, patients with pain around the medial epicondyle, patient not willing to participate in the study and history of alcohol or patient not able to follow commands due to any neurological issue or psychiatric issue.

Design outcomes

Primary

MeasureTime frame
VAS;

Secondary

MeasureTime frame
SF-12;qDASH;

Countries

Pakistan

Contacts

Public ContactEjaz Ali Chaudhry

Ghurki Trust and Teaching Hospital

dr.aliejaz84@gmail.com+44 73 09026936

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026